Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

SELL
$0.65 - $1.25 $153,985 - $296,125
-236,900 Reduced 72.63%
89,270 $61,000
Q2 2023

Aug 11, 2023

SELL
$1.08 - $1.65 $78,948 - $120,615
-73,100 Reduced 18.31%
326,170 $391,000
Q1 2023

May 12, 2023

SELL
$0.78 - $1.42 $7,722 - $14,058
-9,900 Reduced 2.42%
399,270 $467,000
Q4 2022

Feb 13, 2023

BUY
$0.79 - $1.28 $14,536 - $23,552
18,400 Added 4.71%
409,170 $323,000
Q3 2022

Nov 14, 2022

BUY
$0.14 - $1.33 $1,442 - $13,699
10,300 Added 2.71%
390,770 $473,000
Q2 2022

Aug 12, 2022

BUY
$0.88 - $1.87 $300,229 - $637,987
341,170 Added 868.12%
380,470 $350,000
Q1 2022

May 13, 2022

BUY
$1.38 - $1.89 $54,233 - $74,277
39,300 New
39,300 $70,000
Q4 2021

Feb 11, 2022

SELL
$1.51 - $2.2 $1.34 Million - $1.95 Million
-888,501 Closed
0 $0
Q3 2021

Nov 12, 2021

SELL
$1.74 - $2.6 $1.76 Million - $2.63 Million
-1,009,850 Reduced 53.2%
888,501 $1.8 Million
Q2 2021

Aug 13, 2021

BUY
$1.51 - $4.23 $1.37 Million - $3.85 Million
909,255 Added 91.93%
1,898,351 $6.61 Million
Q1 2021

May 13, 2021

BUY
$1.04 - $2.34 $1.01 Million - $2.26 Million
967,819 Added 4548.66%
989,096 $1.76 Million
Q4 2020

Feb 10, 2021

BUY
$0.9 - $1.2 $19,149 - $25,532
21,277 New
21,277 $22,000
Q2 2020

Aug 13, 2020

SELL
$0.65 - $1.45 $59,995 - $133,835
-92,300 Closed
0 $0
Q1 2020

May 14, 2020

BUY
$0.46 - $1.3 $42,458 - $119,990
92,300 New
92,300 $55,000
Q3 2019

Nov 13, 2019

SELL
$0.72 - $1.38 $36,959 - $70,839
-51,333 Closed
0 $0
Q2 2019

Aug 12, 2019

SELL
$0.93 - $1.38 $18,786 - $27,875
-20,200 Reduced 28.24%
51,333 $50,000
Q1 2019

May 14, 2019

SELL
$0.86 - $1.53 $3,956 - $7,038
-4,600 Reduced 6.04%
71,533 $102,000
Q4 2018

Feb 13, 2019

BUY
$0.99 - $1.89 $75,371 - $143,891
76,133 New
76,133 $79,000

Others Institutions Holding CTXR

About Citius Pharmaceuticals, Inc.


  • Ticker CTXR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 146,130,000
  • Market Cap $376M
  • Description
  • Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic l...
More about CTXR
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.